

Gene Set		IC(Δ)	p-value	FDR
	C7			
	SENESE_HDAC2_TARGETS_UP	0.794(0.004)	2.62e-06	5.73e-06
	SENESE_HDAC1_TARGETS_UP	0.783(0.005)	2.62e-06	5.73e-06
	BROWNE_HCMV_INFECTION_2HR_DN	0.782(0.006)	2.62e-06	5.73e-06
	XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR	0.779(0.004)	2.62e-06	5.73e-06
	SENESE_HDAC1_AND_HDAC2_TARGETS_UP	0.774(0.005)	2.62e-06	5.73e-06
	AMIT_EGF_RESPONSE_480_HELA	0.771(0.005)	2.62e-06	5.73e-06
	BMI1_DN_MEL18_DN.V1	0.765(0.004)	2.62e-06	5.73e-06
	AMIT_EGF_RESPONSE_480_MCF10A	0.763(0.005)	2.62e-06	5.73e-06
	MEL18_DN.V1	0.759(0.004)	2.62e-06	5.73e-06
	KIM_WT1_TARGETS_12HR_DN	0.759(0.006)	2.62e-06	5.73e-06
	AMIT_EGF_RESPONSE_240_HELA	0.755(0.005)	2.62e-06	5.73e-06
	HUANG_DASATINIB_RESISTANCE	0.753(0.006)	2.62e-06	5.73e-06
	XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP	0.748(0.005)	2.62e-06	5.73e-06
	HUANG_DASATINIB_RESISTANCE_UP	0.744(0.006)	2.62e-06	5.73e-06
	KRAS.DF.V1_UP	0.738(0.006)	2.62e-06	5.73e-06
	PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2	0.736(0.006)	2.62e-06	5.73e-06
	NIELSEN_LEIOMYOSARCOMA	0.734(0.005)	2.62e-06	5.73e-06
	FULCHER_INFLAMMATORY_RESPONSE_LLECTIN_VS_LPS_UP	0.731(0.005)	2.62e-06	5.73e-06
	BMI1_DN.V1	0.731(0.005)	2.62e-06	5.73e-06
	ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN	0.730(0.007)	2.62e-06	5.73e-06
	BROWNE_HCMV_INFECTION_10HR	-0.638(0.008)	2.62e-06	1.66e-05
	GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT	-0.646(0.007)	2.62e-06	1.66e-05
	LEE_LIVER_CANCER_SURVIVAL	-0.654(0.007)	2.62e-06	1.66e-05
	BROWNE_HCMV_INFECTION_8HR	-0.655(0.006)	2.62e-06	1.66e-05
	RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY	-0.657(0.007)	2.62e-06	1.66e-05
	ESC_V6.5_UP_EARLY.V1	-0.658(0.007)	2.62e-06	1.66e-05
	GHO_ATF5_TARGETS	-0.659(0.007)	2.62e-06	1.66e-05
	PETROVA_PROX1_TARGETS	-0.663(0.008)	2.62e-06	1.66e-05
	BROWNE_HCMV_INFECTION_14HR	-0.665(0.008)	2.62e-06	1.66e-05
	RIGGI_EWING_SARCOMA_PROGENITOR	-0.671(0.007)	2.62e-06	1.66e-05
	RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY	-0.672(0.006)	2.62e-06	1.66e-05
	WEINMANN_ADAPTATION_TO_HYPOXIA	-0.693(0.006)	2.62e-06	1.66e-05
	BROWNE_HCMV_INFECTION_20HR	-0.695(0.007)	2.62e-06	1.66e-05
	KUNINGER_IGF1_VS_PDGFB_TARGETS	-0.697(0.005)	2.62e-06	1.66e-05
	SRC_UP.V1	-0.711(0.005)	2.62e-06	1.66e-05
	OSADA_ASCL1_TARGETS	-0.737(0.006)	2.62e-06	1.66e-05
	CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL	-0.741(0.006)	2.62e-06	1.66e-05
	PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD	-0.742(0.005)	2.62e-06	1.66e-05
	KOBAYASHI_EGFR_SIGNALING_6HR	-0.752(0.004)	2.62e-06	1.66e-05
	REN_ALVEOLAR_RHABDOMYOSARCOMA	-0.762(0.006)	2.62e-06	1.66e-05